Metropolis Therapeutics’ lead RNA interference remedy may change into an alternative choice to blockbuster-selling anticoagulants. The corporate’s expertise for designing RNAi medicine and delivering them to tissues all through the physique has already led to partnerships with Bausch + Lomb in eye illnesses and Biogen in central nervous system issues.
The submit Metropolis Therapeutics’ Upsized IPO Raises $200M to Deliver RNAi Medicine Past the Liver appeared first on MedCity Information.

